Previous 10 | Next 10 |
These Penny Stocks Are Reporting Key Data This Week Looking for penny stocks to buy can be a task especially if there are many to choose from. When it comes to weekend research one of the main search topics involves potential catalysts. So you might say, “It’s the weekend, no o...
Deals and Financings Nanjing Legend Biotech, a subsidiary of GenScript (HK: 1548) (GNNSF), has filed for an IPO on a US exchange. In 2017, Legend surprised the world when its CAR-T therapy produced a 94% response rate in pretreated multiple myeloma patients. Six months later, Johnson &am...
ZAGG (NASDAQ: ZAGG ) -44% after ending strategic review with no deal and Q4 earnings. More news on: ZAGG Inc, Sasol Limited, Party City Holdco Inc., Stocks on the move, , Read more ...
Clearside Biomedical, Inc. (CLSD) Q4 2019 Earnings Conference Call March 11, 2020 4:30 PM ET Company Participants Jenny Kobin - Head, Investor Relations George Lasezkay - President & Chief Executive Officer Thomas Ciulla - Chief Medical Officer Charles Deignan - Chief Finan...
While The Stock Market Slides, These Penny Stocks Are Pushing Higher The markets have swung up and down in dramatic fashion this week. Wednesday’s session was no different and the S&P ETF ( SPY – ETF Report ), for example, dropped over 5%. Meanwhile, the U.S. President is ...
Clearside Biomedical (NASDAQ: CLSD ) has out-licensed development and commercialization rights to Xipere (triamcinolone acetonide suprachoroidal injectable suspension) in Greater China (mainland China, Hong Kong, Macau and Taiwan) and South Korea to Arctic Vision. ...
Clearside Biomedical (NASDAQ: CLSD ): Q4 GAAP EPS of -$0.07 misses by $0.01 . More news on: Clearside Biomedical, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...
- IND Submission for CLS-AX (axitinib injectable suspension) On Track for Mid-2020 - - Greater China Licensing Partnership and Updated NDA Resubmission Timeline for XIPERE™ (triamcinolone acetonide suprachoroidal injectable suspension) - - Partners Expected to Initiate Clinical ...
– Arctic Vision to Lead Expansion of Novel Approach to Treating Macular Edema Associated with Uveitis in Asia – – Clearside Eligible to Receive Upfront and Milestone Payments and Royalties on Product Sales – – Increasing Global Awareness of Innovative...
ALPHARETTA, Ga., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that its fourth ...
News, Short Squeeze, Breakout and More Instantly...
Clearside Biomedical Inc. Company Name:
CLSD Stock Symbol:
NASDAQ Market:
Clearside Biomedical Inc. Website:
ALPHARETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), has opened registration for its virtual key opinion l...
ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today the appointment of Glenn C. Yiu, M.D....
- Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ...